Shares of Butterfly Network surged 10.6% to $9.00 on September 22 after Needham analyst David Saxon initiated coverage with a Buy rating and a $10.00 price target — the clearest catalyst behind the sharp single-day move. The call hands BFLY its second major Wall Street endorsement, joining TD Cowen, which has consistently maintained a Buy rating with a matching $10.00 target . For a stock that traded below $2 as recently as early 2026, the question is whether operating results can keep pace with a now-lofty market value.

  • The Analyst's Thesis: A Chip That Could Spread Far Beyond Handheld Devices. Saxon cited the company's proprietary semiconductor-based ultrasound chip as a differentiator, saying it "is enabling the development of a new wave of medical technologies that spans many categories." In plain terms, Butterfly's core chip can be embedded inside other companies' medical products — not just sold as a standalone scanner. The analyst noted multiple sources of potential upside from this core platform. That embedded licensing model, if it scales, could diversify revenue well beyond one-off device sales.

  • The Numbers Are Improving — Fast. Butterfly posted record Q2 revenue of $32.6 million, up 39% year-over-year, with gross margins hitting 71%, a 770-basis-point (roughly 8 percentage point) improvement.

Management subsequently raised its full-year 2026 revenue outlook to $119–$123 million . That trajectory matters: it shows the company is growing quickly and keeping more of each dollar.

  • Losses and Insider Selling Cloud the Picture. Butterfly still lost $12.91 million in Q2 alone and $25.59 million in the first half of 2026. Meanwhile, founder Jonathan Rothberg sold roughly 4 million shares worth approximately $29.4 million in mid-July , under a prearranged trading plan for estate planning.

Shares outstanding have grown 15.7% in one year , meaning existing investors are being diluted — their slice of the company is shrinking.

  • Valuation Leaves Little Room for Error. At $9.00 per share and roughly 261.6 million shares outstanding , Butterfly commands a market value near $2.4 billion against trailing twelve-month revenue just above $100 million — a price-to-sales ratio above 20×. GF Value pegs fair value at just $2.47, labeling the stock nearly 230% overvalued. Saxon's $10 target implies only another 11% of upside from today's price, meaning most of the Needham-driven rally has already been captured.

Bottom line: Needham's initiation validates Butterfly's technology story, but the stock now prices in years of growth from a company still burning cash and diluting shareholders.